Financial Survey: Cypherpunk Technologies (NASDAQ:CYPH) versus Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Cypherpunk Technologies (NASDAQ:CYPH) and Provectus Biopharmaceuticals (OTCMKTS:PVCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares Cypherpunk Technologies and Provectus Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-316.09%	-176.06%
Provectus Biopharmaceuticals	-1,374.19%	N/A	-942.72%

Volatility & Risk

Cypherpunk Technologies has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, Provectus Biopharmaceuticals has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Insider & Institutional Ownership

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 0.1% of Provectus Biopharmaceuticals shares are held by institutional investors. 4.3% of Cypherpunk Technologies shares are held by insiders. Comparatively, 12.8% of Provectus Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Cypherpunk Technologies and Provectus Biopharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	-$67.56 million	($1.22)	-0.54
Provectus Biopharmaceuticals	$620,000.00	30.17	-$4.76 million	N/A	N/A

Provectus Biopharmaceuticals has higher revenue and earnings than Cypherpunk Technologies.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cypherpunk Technologies and Provectus Biopharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1	1	0	0	1.50
Provectus Biopharmaceuticals	0	0	0	0	0.00

Summary

Provectus Biopharmaceuticals beats Cypherpunk Technologies on 5 of the 9 factors compared between the two stocks.

About Cypherpunk Technologies

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.